5 years ago

Risk of Infection in Patients with Atopic Dermatitis Treated with Dupilumab: A Meta-Analysis of Randomized Controlled Trials

Atopic dermatitis (AD) is characterized by skin barrier defects, Th2 activation, and increased risk for cutaneous and extracutaneous infections. In clinical trials, dupilumab appeared to decrease rates of skin infections in AD. Objective We aimed to determine the impact of dupilumab on rates of skin and other infections in patients with moderate-to-severe AD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of dupilumab for AD. We searched the PubMed database for relevant studies. Risk ratios (RR) and 95% confidence intervals (CI) for skin infections, herpesvirus infections and overall infections and infestations were calculated for dupilumab compared with placebo using binary random-effects meta-analysis. For the analysis of eczema herpeticum, Peto odds ratios (OR) were calculated. Results Eight RCTs in 4 publications with 2,706 participants were included with follow-up time ranging from 4-52 weeks. Meta-analysis including all dosing schedules and follow-up times showed a RR of skin infection of 0.54 (95% CI: 0.42-0.70) and an OR of eczema herpeticum of 0.34 (95% CI: 0.14-0.84) for dupilumab compared with placebo. No significant association was found for dupilumab with overall herpesvirus infections (RR=1.16, 95% CI: 0.78-1.74) and overall infections (RR=0.98, 95% CI: 0.83-1.16). Limitations Our analysis is limited by short follow-up time in most trials and relatively low number of patients treated with dupilumab to date. Conclusion Dupilumab is associated with a decreased incidence of skin infections and eczema herpeticum in adults with moderate-to-severe AD. The mechanism underlying this association is uncertain, but is likely related to improvement in AD severity.

Publisher URL: www.sciencedirect.com/science

DOI: S019096221732457X

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.